Ultrasound-targeted microbubble destruction for chemotherapeutic drug delivery to solid tumors.
Ultrasound-targeted microbubble destruction for chemotherapeutic drug delivery to solid tumors.
复制标题
DOI：
10.1186/2050-5736-1-10
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Hwang JH
中科院分区：
文献类型：
--
作者：
Chen H;Hwang JH
超声靶向微泡破坏（UTMD）是一种有前途的非侵入性靶向药物输送技术，其在实体瘤化疗药物输送中的应用引起了越来越多的兴趣。超声波通常用于诊断成像，现已发展成为一种有前途的治疗应用工具，主要是因为它能够聚焦在人体深处，提供了一种靶向输送的方式。尽管微泡 (MB) 最初作为超声造影剂引入诊所，但现已发展为一种诊断和治疗剂，既可以通过非侵入性成像进行跟踪，又可以在超声目标位置选择性地输送治疗剂。尽管游离药物通常具有有害的副作用，但将其封装在 MB 中并随后通过超声触发在目标组织进行局部释放可能有助于提高安全系数。在过去的10年里，UTMD的可行性和安全性已经使用正常动物模型进行了广泛的测试。最近，越来越多的临床前研究报道了 UTMD 在向各种恶性肿瘤（如脑肿瘤、肝脏肿瘤、眼睑肿瘤、胰腺肿瘤和乳腺肿瘤）输送化疗药物方面的治疗益处。与单独使用化疗药物治疗的肿瘤相比，使用 UTMD 联合化疗药物治疗的肿瘤实现了肿瘤药物浓度的增加和肿瘤尺寸的减小。本综述概述了目前 UTMD 在癌症化疗药物输送中的临床前应用，并讨论了其未来发展。
Ultrasound-targeted microbubble destruction (UTMD) is a promising technique for non-invasive, targeted drug delivery, and its applications in chemotherapeutic drug delivery to solid tumors have attracted growing interest. Ultrasound, which has been conventionally used for diagnostic imaging, has evolved as a promising tool for therapeutic applications mainly because of its ability to be focused deep inside the human body, providing a modality for targeted delivery. Although originally being introduced into clinics as ultrasound contrast agents, microbubbles (MBs) have been developed as a diagnostic and therapeutic agent that can both be tracked through non-invasive imaging and deliver therapeutic agents selectively at ultrasound-targeted locations. Whereas free drugs often possess harmful side effects, their encapsulation in MBs and subsequent local release at the targeted tissue by ultrasound triggering may help improve the margin of safety. In the past 10 years, the feasibility and safety of UTMD have been extensively tested using normal animal models. Most recently, a growing number of preclinical studies have been reported on the therapeutic benefits of UTMD in the delivery of chemotherapeutic drugs to various malignant tumors, such as brain, liver, eyelid, pancreas, and breast tumors. Increased drug concentration in tumors and reduced tumor sizes were achieved in those tumors treated with UTMD in combination with chemotherapeutic drugs, when compared to tumors treated with chemotherapy drugs alone. This review presents an overview of current preclinical applications of UTMD in chemotherapeutic drug delivery for the treatment of cancers along with a discussion of its future developments.